MA-HOLOGIC
25.5.2022 14:04:04 CEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX) announced it has received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system. The assays quantify the viral load of the respective viruses and are intended to aid the diagnosis and management of solid organ transplant patients and hematopoietic stem cell transplant patients.
The assays are in vitro nucleic acid amplification tests (NAAT) that are run on the fully automated Panther Fusion system using real-time Polymerase Chain Reaction (PCR) technology. The Panther Fusion EBV Quant is validated for use with whole blood and plasma samples. The Panther Fusion BKV Quant is validated for use with human plasma and urine samples. Plasma, whole blood and urine specimens are important biomarkers when using quantitative NAATs for diagnosis and management of transplant patients. It is crucial that viral levels are accurately quantitated in transplant recipients to guide treatment decisions and monitor response to therapy.1,2
“Immunocompromised patients are vulnerable to a range of infections. As both the Epstein-Barr virus (EBV) and the BK virus (BKV) are extremely common and mainly asymptomatic, it is important that healthcare providers can quantitate and monitor for their presence,” said Jan Verstreken, Group President, International at Hologic. “These assays, along with our Aptima CMV Quant assay that we launched in Europe last year, provide our laboratory partners with the tools they need to accurately assess transplant patient samples quickly and confidently.”
“These two assays represent two firsts for us. They are the first quantitative assays developed for the Panther Fusion system, further expanding our existing portfolio of diagnostic and viral load tests. They are also the first Panther Fusion assays developed in our R&D facility in Liege, Belgium, which we acquired last year,” concluded Verstreken.
For more information on the Aptima and Panther Fusion assays, visit www.hologic.com .
About Epstein-Barr Virus
EBV is a ubiquitous virus that belongs to the herpesvirus family. It is estimated that 90% of the population worldwide is infected with EBV.3 In immunocompromised people such as transplant patients, it is a significant cause of morbidity and mortality.
About BK Virus
BKV is a highly prevalent human polyomavirus that belongs to the papoviridae family. Primary exposure to BKV occurs in childhood, resulting in 80-90% of adults having developed antibodies against BKV. The majority of BKV infections are asymptomatic, with the virus remaining latent in the urinary tract.4 Viral reactivation occurs in immunocompromised individuals, frequently in renal transplant and hematopoietic stem cell transplant patients, and is associated with nephropathy, ureteral stenosis and late onset haemorrhagic cystitis.5
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Hologic Forward-Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, The Science of Sure, Aptima, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. in the United States and/or other countries.
Source: Hologic, Inc.
References
- Nijland, ML, Kersten MJ, Pals ST, Bemelman FJ, ten Berge JJM. 2016 Transplantation Direct 2016;2: e48 doi: 10.1097/TXD.0000000000000557.
- Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. 2019. BK polyomavirus in solid organ transplantation–Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. Sep;33(9): e13528.doi:10.1111/ctr.13528. Epub 2019 Apr 10. PMID:30859620.
- Tzellos S, Farrell PJ. 2012. Epstein-Barr Virus Sequence Variation—Biology and Disease. Pathogens. 1(2):156–174. doi.org/10.3390/ pathogens1020156.
- Muhsin SA, Wojciechowski D. 2019. BK Virus In transplant recipients: current perspectives. Transpl Res Risk Manag. 11:47-58.
- van Aalderen MC, Heutinck KM, Huisman C, et al. 2012. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med. May;70(4):172-183. PMID:264162.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds22.6.2026 14:30:00 CEST | Press release
New global study shows normalization of strategic returns, widening regional differences, and rapid AI adoption reshaping ecommerce post-purchase risk Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today released a new global report, “Rewriting the Rules on Returns”, exploring how consumer attitudes and behaviors around ecommerce returns are evolving in the age of artificial intelligence (AI). The Riskified-commissioned study, conducted by eTail Insights, is based on a survey of 2,091 consumers across seven countries, alongside in-depth interviews with senior leaders from many of the largest retail companies in the world. The research finds that return abuse behaviors are increasingly normalized, while nearly half of consumers already use generative AI tools to assist with return or refund claims. At the same time, merchants are responding by tightening return policies, shortening return windows, and deploying advanced AI detection to better
Forrester Unveils Agendas For 2026 Technology & Innovation Forums In North America And EMEA22.6.2026 14:00:00 CEST | Press release
The Forums will equip technology leaders with the capabilities needed to operationalize AI and build high-performing IT organizations that deliver measurable business outcomes Forrester (Nasdaq: FORR) today announced the full conference agendas for its Technology & Innovation Forum Central (Austin, September 14–15, 2026), Technology & Innovation Forum EMEA (London, September 30–October 1, 2026), and Technology & Innovation Forum East (New York City, November 4–5, 2026). This year’s theme, “The IT Singularity,” dives into the new AI era in which AI has become ubiquitous and no longer a competitive advantage on its own. To succeed, technology leaders including chief information officers, chief data officers, and chief AI officers need to integrate AI into their operating models, modernize software development and IT operations, strengthen data and governance practices, and align technology investments with business strategy. Across the Forums, tech leaders and their teams will learn how
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy22.6.2026 14:00:00 CEST | Press release
New 128,000-square-foot facility in Andover will serve as U.S. global headquarters and future manufacturing center supporting the development and commercialization of ADVC001 and the Company’s pipeline of Lead-212 targeted alpha therapies Expanding U.S. operations complement the Company’s established Australian R&D and manufacturing capabilities to create a global, vertically integrated platform for radiopharmaceutical development and commercial supply AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the establishment of its U.S. Global Headquarters in the Greater Boston area, and the lease of a new 128,000-square-foot facility that will become the Company’s U.S. flagship manufacturing center supporting its long-term growth and commercialization strategy. The expansion marks an important milestone in the Company’s evolution into a U.S.-based radiopharmaceutical company with integrated operations spanning
Print Creates an Enterprise Dark Data Problem. VasionⓇ Innovated Again to Find the Solution.22.6.2026 14:00:00 CEST | Press release
Intelligent Print Automation Turns the File > Print Workflow Into an AI-Ready Data Pipeline Every time employees click File > Print to send documents to printers, save them to PDFs or scan them to unmanaged folders, enterprise data becomes unstructured and quietly goes dark. Dark data escapes compliance controls, bypasses AI workflow and quickly becomes a liability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622562749/en/ Vasion is the Intelligent Print Automation leader making digital transformation attainable for all by eliminating print servers, consolidating print environments, digitizing and automating workflows. Gartner® reports that “roughly 80% of enterprise information is unstructured, spread across documents, files, and rich content in dozens of systems.” Gartner® also predicts that “by 2028, large enterprises will triple their unstructured data capacity across their on-premises, edge and public cloud locati
HistoSonics Announces Financing with Participation from Yosemite Among Other Strategic Investors22.6.2026 14:00:00 CEST | Press release
Values Company at $3.75 Billion and Funds Development of Additional Clinical Applications HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new financing round with participation from Reed Jobs and Yosemite, whose aim is to “make cancer non-lethal in our lifetime,” alongside several new strategic investors. Additional financing terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622435314/en/ HistoSonics Edison® Histotripsy System The financing comes amid significant momentum for HistoSonics as the company continues to expand clinical adoption of histotripsy for liver tumors around the world and is quickly advancing additional applications of its non-invasive platform across solid tumors. "Building a generational company requires partners who bring more than capital,” commented Mike Blue, Chairman & CEO, HistoSonics.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom